The beta-3 adrenergic agonist (CL-316,243) restores the expression of down-regulated fatty acid oxidation genes in type 2 diabetic mice

Table 6 Metabolic parameters from WT and MKR mice at baseline, and after 2 weeks of treatment with CL-316,243 tor vehicle

	WT vehicle		WT CL-316,243		MKR vehicle		MKR CL-316,243
	Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks	Baseline	2 weeks
Body weight (g)	27.95 (0.93)	28.47 (1.13)	28.03 (0.48)	27.15 (0.55)	23.97 (1.07)^a	24.19 (0.63)	22.15 (0.59)	22.16 (0.23)
Blood glucose (mg/dL)	146.43 (2.89)	157.29 (6.71)	152.75 (5.55)	184.88 (10.28)	387.60 (52.33)^a	380.80 (24.37)	335.40 (36.10)	226.20 (16.23)^b
Body fat (%)	14.02 (1.26)	12.83 (1.36)	12.58 (0.92)	6.41 (0.51)^c	11.28 (0.71)	11.00 (1.07)	12.45 (0.77)	4.46 (0.40)^b
Serum TG (mmol/L)		2.29 (0.06)		1.62 (0.03)^d		4.90 (0.10)^e		3.77 (0.04)^f
Plasma insulin (ng/ml)		1.50 (0.97)		0.82 (0.51)		8.58 (3.85)^e		0.80 (0.28)^f

Metabolic parameters from wild type (WT) and MKR mice at baseline and after 2 weeks of treatment with CL-316,243. Data in table are means of each group and SEM in parenthesis. One Way ANOVA analysis and Tukey-Kramer post-hoc significance test was performed, assuming a significance level of 5%. The following differences in the group means were found: ^aMKR Vehicle Baseline vs WT Vehicle Baseline; ^bMKR CL-316,243 2 weeks vs MKR CL-316,243 Baseline; ^cWT CL-316,243 2 weeks vs WT CL-316,243 Baseline; ^dWT CL-316,243 2 weeks vs WT Vehicle 2 weeks; ^eMKR Vehicle 2 weeks vs WT Vehicle 2 weeks; ^fMKR CL-316,243 2 weeks vs MKR Vehicle 2 weeks.

ISSN: 1743-7075